SLAMF7 and Miyoshi myopathy: Elotuzumab, an immunostimulatory mAb targeting signaling lymphocytic activation molecule F7 (SLAMF7), did not show an effective anti-MM activity as single agent, but showed activity in combination with lenalidomide and pomalidomide in patients with relapsed/refractory (RR)MM, even if it failed in the first-line setting [137,138,139].